review of glp 1 Glucagon-like peptide-1 receptor agonists and risk gastrointestinal cancers: A systematic and meta-analysis of randomized controlled trials GLP-1 receptor agonists effective for

DO NOT hack GLP-1 pens

Regulatory & Approval Risks Navigating the regulatory environment is a challenge in developing weight loss drugs

508,509,510,511 Additionally, GLP-1 mitigates liver inflammation and fibrosis by inhibiting the NF-B pathway, reducing the release of pro-inflammatory cytokines such as TNF- and IL-6, and thus suppressing inflammatory pathways

Recent FDA approvals have included indications for cardiovascular risk reduction, and others are anticipated for conditions like obstructive sleep apnea and chronic kidney disease

Questions to Ask Yourself: Am I comfortable with compounded medications that have not been FDA-reviewed as finished products

Pflugers Arch Eur J Physiol 460(1):6976